John Hawley

New Council members elected, 2020

Posted on by John Hawley

The ASCI is pleased to announce the results of a recent ballot to fill Council vacancies pending in 2020. Dr. Benjamin Humphreys, Secretary-Treasurer Elect, oversaw the ballot; Drs. Wonder Drake and Anna Hemnes volunteered as auditors.

The following members will join the Council at the conclusion of the upcoming AAP/ASCI/APSA Joint Meeting, April 3-5.

Vice President: Sohail F. Tavazoie, MD, PhD


Dr. Tavazoie

Dr. Tavazoie is Leon Hess Professor and Senior Attending Physician at the Rockefeller University. He received his MD from Harvard Medical School and PhD from Harvard University, completed his internship and residency in internal medicine at the Brigham and Women’s Hospital/Harvard Medical School, and completed a fellowship in oncology at the Sloan Kettering Institute. Elected to the ASCI in 2015, he currently serves on the Council as a Councilor.

Read more about Dr. Tavazoie

Secretary-Treasurer Elect: Priscilla Ying Hsue, MD


Dr. Hsue

Dr. Hsue is the William Watt Kerr Professor of Medicine and Co-Director, Center of Vascular Excellence, at the University of California, San Francisco (UCSF). She received an MD from UCSF, where she completed her internship and residency. Dr. Hsue was elected to the ASCI in 2013.

Read more about Dr. Hsue

Councilor: Jennifer A. Wargo, MD, MMSc


Dr. Wargo

Dr. Wargo is Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. She received an MD from the Medical College of Pennsylvania, completed a clinical internship and residency in general surgery at the Massachusetts General Hospital (MGH); a research fellowship in surgical oncology at the University of California, Los Angeles; a clinical residency in general surgery at MGH; and a clinical fellowship in surgical oncology at the National Cancer Institute. She received an MMSc from Harvard University in 2012. She was elected to the ASCI in 2019.

Read more about Dr. Wargo

The 2020 Stanley J. Korsmeyer Award: Judith A. James, MD, PhD

Posted on by John Hawley
Dr. James

Judith A. James, MD, PhD, is the recipient of the 2020 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation (ASCI) for her contributions to understanding the mechanisms of systemic autoimmune diseases.

Dr. James earned her BS from Oklahoma Baptist University in 1989 and her PhD and MD from the University of Oklahoma Health Sciences Center (OUHSC) in 1993 and 1994, respectively. From 1993 to 1995, she was a postdoctoral fellow at the Oklahoma Medical Research Foundation (OMRF) in the laboratory of John Harley, MD, PhD. At OUHSC, she completed her internship and residency in internal medicine and a fellowship in rheumatology.

Systemic autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), arise from dysregulation of the immune system. This dysregulation signals immune cells to target a person’s normal proteins, protein complexes, tissues, and organs, creating potentially extremely damaging inflammation and shortened lifespans. Dr. James has focused on identifying changes in the immune system before clinical diagnosis of disease. In 2003, she and her collaborators used the US Department of Defense Serum Repository to identify SLE autoantibodies in samples collected from military personnel before their diagnosis with SLE; this research demonstrated that one or more of these autoantibodies are present for several years before diagnosis and that they progressively accumulate before the appearance of disease symptoms. This work has since progressed to a US multicenter clinical trial, initiated in 2017, to identify people who are at high risk for developing SLE and to treat them with hydroxychloroquine before the onset of disease, with the goal of delaying onset and disease severity.

Dr. James’s research has been supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the National Institute of Allergy and Infectious Diseases, and the National Institute of General Medical Sciences, among other sources.

In addition to her body of research now comprising more than 280 journal articles, Dr. James has a deep mentoring history spanning the student spectrum and postdoctoral fellows, with a particular dedication to America Indian and underrepresented minority trainees.

Dr. James, a native of Pond Creek, Oklahoma, began her affiliation with OMRF as a Sir Alexander Fleming Scholar in 1988. She joined the scientific staff of OMRF in 1994. She is Vice President of Clinical Affairs, OMRF, and Associate Vice Provost for Clinical and Translational Science, OUHSC. She holds the George Lynn Cross Research Professorship and is Professor of Medicine, Professor of Pathology, and Adjunct Professor of Microbiology and Immunology, OUHSC; and is Lou C. Kerr Endowed Chair in Biomedical Research, OMRF.

Dr. James has received national and international recognition for her achievements, including the US Presidential Early Career Award for Scientists and Engineers (2000); the Edmund L. Dubois, MD, Memorial Lectureship, Research and Education Foundation of the American College of Rheumatology (2007); the Paul Klemperer, MD, Memorial Lectureship of the American College of Rheumatology (2019), and the Evelyn V. Hess, MD Award from the Lupus Foundation of America (2019). She was elected to the Henry Kunkel Society in 2002 and to the ASCI in 2003. Dr. James served from 2012 to 2015 on the ASCI Council as Secretary-Treasurer Elect and Secretary-Treasurer.

[insert page=’k20-banner-ad’ display=’content’]

The 2019 Nobel Prize in Physiology or Medicine

Posted on by John Hawley

The ASCI is pleased to recognize the three joint recipients of the 2019 Nobel Prize in Physiology or Medicine: William G. Kaelin Jr., MD, Sir Peter J. Ratcliffe, and Gregg L. Semenza, MD, PhD. The Prize, announced October 7, was awarded to the researchers for their discoveries of how cells sense and adapt to oxygen availability.

From left to right: William Kaelin, Peter Ratcliffe, and Gregg Semenza. Image credits (left to right): Sam Ogden/Dana-Farber Cancer Institute, Paul Wilkinson Photography, Jay VanRensselaer/Johns Hopkins Medicine.

 

Dr. Kaelin is Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, and a Howard Hughes Medical Institute Investigator. Along with this honor, he shared the 2016 Albert Lasker Basic Medical Research Award with Sir Peter and Dr. Semenza and the 2012 ASCI | Stanley J. Korsmeyer Award with Dr. Semenza. He is a member of the National Academy of Sciences (elected 2010), the National Academy of Medicine (2007), and the ASCI (1997, view profile).

Sir Peter is Director of the Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, and a Member of the Ludwig Institute for Cancer Research. He shared the 2016 Albert Lasker Basic Medical Research Award with Drs. Kaelin and Semenza. Dr. Ratcliffe is a Fellow of the Royal Society and the Academy of Medical Sciences and an honorary member of the American Academy of Arts and Sciences.

Dr. Semenza is the C. Michael Armstrong Professor of Medicine at the Johns Hopkins University School of Medicine and Director of the Vascular Research Program at the Johns Hopkins Institute for Cell Engineering. He shared the 2016 Albert Lasker Basic Medical Research Award with Dr. Kaelin and Sir Peter and the 2012 ASCI | Stanley J. Korsmeyer Award with Dr. Kaelin. He is a member of the National Academy of Medicine (2012), the National Academy of Sciences (elected 2008), and the ASCI (1995, view profile).

Read more:

Call for nominations: 2020 Young Physician-Scientist Awards

Posted on by John Hawley

The ASCI is pleased to call for nominations for the ASCI’s 2020 Young Physician-Scientist Awards. This is an excellent opportunity for a young faculty member to be recognized at the 2020 Joint Meeting.

We seek nominations from ASCI members of outstanding physician-scientists who have recently received their first faculty appointment (preferably in the last 5 years).

Nominees must be funded by a current NIH K or equivalent career-development award (in or outside the United States). However, we welcome nominations of NIH intramural physician-scientists on the basis of their appointment only. See nomination form for detail.

Those selected for this Awards program will:

  • receive a $500 travel award to attend the 2020 Joint Meeting, April 3-5, at the Fairmont Chicago
  • present their work at the ASCI’s Food & Science Evening, Saturday, April 4

Up to 40 Awards will be given for 2020. The following materials are required for nominations, which must be submitted by nominating members through their accounts on or before the extended deadline, December 3, 2019, at 11:59 pm, U.S. Eastern:

  • Nomination form: download form
    Note: For the requested abstract, it should not be submitted separately to the Joint Meeting for consideration; it should only be submitted for consideration as part of the nomination.
  • NIH-style biosketch

Call for nominations, 2020 Seldin~Smith Award

Posted on by John Hawley

The ASCI is pleased to call for nominations for the 2020 Donald Seldin~Holly Smith Award for Pioneering Research. The Award seeks to recognize and connect the next generation of physician-scientist leaders with the legacies of two of the ASCI’s most esteemed members, Drs. Donald W. Seldin and Lloyd H. “Holly” Smith Jr.

For the Award, the ASCI seeks nominations of outstanding physician-scientists who have demonstrated exceptional creativity and accomplishments in biomedical research. The ideal nominee:

  • is an early-stage, clinically active physician-scientist addressing fundamental questions that relate to human health and disease, and
  • shows great promise in biomedicine.

The recipient of the Seldin~Smith Award will receive an unrestricted grant of $30,000 to advance academic efforts. S/he will be recognized at the 2020 AAP/ASCI/APSA Joint Meeting, deliver a research talk at the 2021 Joint Meeting, and receive mentoring from the members of the Seldin~Smith Award Selection Committee and Advisory Committee.

Eligibility

  • MD (or the equivalent) or MD/PhD;
  • The candidate must be more than 2 years but not more than 6 years from first faculty (or the equivalent) appointment at the time of acceptance in April 2020;
  • The candidate spends substantial time in research while providing direct patient care.

This competition is not restricted to any geographic location.

Application

Physician-scientists should apply directly by sending nominations by email attachments to staff@the-asci.org.

  • Completed nomination form, including:
    • a summary of the nominee’s research (not to exceed 100 words)
    • a description of the nominee’s most significant achievement (not to exceed 500 words).
    • a list of the nominee’s three most significant publications and a short statement describing the significance of each publication (not to exceed 100 words each).
    • Nominee’s agreement, if chosen as the recipient, to attend the 2020 AAP/ASCI/APSA Joint Meeting (April 3-5) and the 2021 AAP/ASCI/APSA Joint Meeting (April 9-11).
  • PDFs of the nominee’s three most significant publications as listed in the nomination form.
  • Nominee’s curriculum vitae (PDF). Include only educational background, major awards, and peer-reviewed publications (do not include abstracts, grants, or meeting presentations).
  • No more than two letters of support (as PDFs), one from the nominee’s primary mentor, the other ideally from an individual who is a recognized expert on the subject of the nominee’s research.

Notable dates and selection process

  • Nomination deadline: November 20, 2019.
  • Recipient will be notified by early 2020.
  • Recipient will be recognized at the 2020 AAP/ASCI/APSA Joint Meeting, April 3-5.
  • Recipient will deliver a research talk at the 2021 AAP/ASCI/APSA Joint Meeting, April 9-11.

The Seldin~Smith Award Selection Committee reviews nominations and selects finalists for further consideration by the Seldin~Smith Award Advisory Committee.

About the ASCI

Founded in 1908, the ASCI is home to physician-scientist leaders in academic medicine and industry across the world. The ASCI seeks to support the scientific efforts, educational needs, and clinical aspirations of physician-scientists to improve human health. The Society, based in the United States, is a nonprofit 501(c)(3) organization.

Call for Council nominations, 2020

Posted on by John Hawley

The Society seeks nominations for the following ASCI Council vacancies arising in 2020 (all terms begin and end in the spring):

  • Vice President (4-year term, 2020-2024),
  • Secretary-Treasurer Elect (3-year term, 2020-2023; first year is Councilor position, transitioning to Secretary-Treasurer for years 2 and 3), and
  • 2 Councilor positions (3-year term, 2020-2023).

All Council members are expected to support the activities of and attend the ASCI annual meeting, and to participate in the general governance of the Society, including two in-person meetings (fall and spring, coordinate with the annual meeting) and conference calls (typically every other month). All Council members participate in the review of membership nominations.

The Vice President transitions to President-Elect in year 2 and President in year 3. For the 2nd through 4th years of this position, this member is expected to participate significantly in matters related to the Joint Meeting. In the Presidential year (year 3), the member convenes a face-to-face Council meeting and oversees related review processes for nominations, notably including those to membership. The President works closely with the Association of American Physicians to create the annual meeting program, and the member presents the traditional Presidential Address at the meeting. In year 4, the President transitions to Immediate Past President, serving as an advisor to the current President and with full Council responsibilities and privileges.

The Council is supported by an Executive Director, Managing Director, and other staff members who oversee the day-to-day operations of the Society and effect initiatives as directed by the Council. For details on Officers and Councilors, see the ASCI Bylaws.

Members who will be 55 or younger in 2023 are eligible for nomination. The Society encourages members to consider diversity in identifying those suitable for nomination. Nominations may be submitted by any member and must be submitted through member accounts. Nominations must be submitted by September 24, 2019, at 11:59 PM EDT, and consist of a 250-word summary of the nominee, an indication for which vacancy (if any) the nominee should be considered, and an NIH-style brief biosketch (PDF only). (Note: Nominees should confirm that they are willing and able to serve on Council if selected; nominees may send a brief email to staff@the-asci.org by the deadline.) Self-nominations are not allowed.

Call for nominations, 2020 Stanley J. Korsmeyer Award

Posted on by John Hawley

Nominations for the ASCI’s 2020 Stanley J. Korsmeyer Award are now open. The recognition, first called the ASCI Award, was renamed in 2006 in honor of Dr. Korsmeyer, the first recipient of the Award in 1998, who passed away in 2005. The Korsmeyer Award recognizes individuals for their advancement of knowledge in a specific field and mentoring of future generations of life science researchers. Information on all past honorees is available here.

Nominees for the Stanley J. Korsmeyer Award must be ASCI members who are 55 years of age or younger as of January 1, 2020. They shall have made significant contributions to biomedical science and shall have adhered to the principles of scientific excellence that the ASCI exemplifies. The nominee should have a record that reflects high standards of intellectual integrity, a deep and abiding respect for the community of biomedical scientists, and a strong commitment to mentoring the next generation of physician-scientists. Prior nominees may be re-nominated. However, current ASCI Council members and prior Award recipients may not be nominated.

Nominations consist of:

  • a summary of the nominee’s accomplishments (in plain text, not to exceed 250 words),
  • a brief NIH biosketch (as a PDF),
  • a full curriculum vitae, including all publications and invited lectures (as a PDF),
  • and a trainee table (preferred as a PDF).

Nominations must be submitted by ASCI members through their online accounts.

The deadline for nominations is September 24, 2019, at 11:59 PM Eastern.

Nominations for 2020 membership

Posted on by John Hawley

Nominations for 2020 membership may be submitted through September 13, 2019. Proposers and supporters of nominations should review the Membership Nomination Guide carefully. Questions regarding nominations should be sent by email to staff@the-asci.org.

Note to submitters: The ASCI sends acknowledgment of submissions by email after they have been reviewed and found to be complete. Submitters can check the status of their submissions (nominations and support forms) online by accessing their member accounts.

Submitting nominations

To ensure proper tracking of nominations, all information and documents must be supplied online.

  • First, access your member account
  • After you have logged in to your account, select the “Nominations” tab, then search the nominee database. Links will appear in search results to guide you in the next steps.
  • Your nominee may already be in the ASCI database because the nominee was previously nominated or because a nomination or support form has been started for the nominee for this nomination cycle.

Proposers: Once you have supplied the requested information about your nominee (name, contact information, etc.), you will be able to upload required documents. You will also be able to add Seconder and General Supporter information to the nomination, although supporters will need to supply their comments via their own member accounts.

Seconder and General Supporters: Forms may be drafted and submitted online after selecting the applicable nominee from search results or after adding requested information about the nominee you are supporting. (NOTE: General Supporters who are not ASCI members may complete the nomination support template and email it to staff@the-asci.org for handling. Please indicate clearly your contact information and the name and institution of the nominee you are supporting.)

Further clarification

  • Age criterion for Active and Foreign Associate nominees. Nominees in these categories must be age 50 or younger as of January 1, 2020.
  • Exceptions to the age criterion cannot be made. Although the ASCI Council understands that a nominee’s progress may have been delayed because of unavoidable or extreme circumstances, the Council has on multiple occasions discussed exceptions and concluded from each discussion that no policy could be implemented fairly and durably.
  • Limit on number of nominations per nominee. The number of nominations per nominee is limited to 3, provided the nominee is age 50 as of January 1, 2020.
  • Limit on number of nominations proposed, seconded, or supported. There is no limit to the number of nominations a member may propose or support (either as Seconder or General Supporter).
  • Ph.D.-only candidates. Active and Foreign Associate nominations are, per the ASCI’s bylaws, restricted to physicians.
  • M.D.-equivalent candidates are eligible for nomination.
  • Faculty appointment versus nominee’s country of residence. The distinction between Active and Foreign Associate nominations is made on the basis of residence, not faculty appointment. Active nominees must reside in the U.S. or Canada. Candidates residing elsewhere should be nominated in the Foreign Associate category.

 

New JCI Insight Editor: Kathleen L. Collins, MD, PhD

Posted on by John Hawley

Dr. Collins begins her tenure as JCI Insight Editor in Chief on September, 1, 2019. She succeeds Dr. Howard A. Rockman, who served as the first Editor in Chief of the journal, which started publication in January 2016. Dr. Collins was elected to the position by the American Society for Clinical Investigation (ASCI) following a selection process that concluded in April 2019. In the position, she will also be a member of the ASCI Council, the leadership body of the ASCI.

Dr. Collins is the University of Michigan Department of Internal Medicine Collegiate Professor of HIV Research, Professor of Microbiology and Immunology, Associate Director of the Cellular and Molecular Graduate Program, and Senior Scholar of the A. Alfred Taubman Medical Research Institute. Her research focuses on viral persistence, including mechanisms by which HIV evades innate and adaptive immune responses. Dr. Collins is a member of the ASCI (elected 2005) and the Association of American Physicians (elected 2012), as well as a member of the National Academy of Medicine (elected 2016).

The 2019 Harrington Prize for Innovation in Medicine: Carl H. June, MD

Posted on by John Hawley

Harrington Discovery Institute and The American Society for Clinical Investigation honor Dr. June for his contributions to the field of cellular immunology

 

 

Dr. June

The sixth annual Harrington Prize for Innovation in Medicine has been awarded to Carl H. June, MD, the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at University of Pennsylvania’s Perelman School of Medicine.

The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio, and The American Society for Clinical Investigation (ASCI), honors physician-scientists who have moved science forward with achievements notable for innovation, creativity and potential for clinical application.

Dr. June is being recognized for advancing the clinical application of CAR T therapy for cancer treatment, and for his sustained contributions to the field. CAR T cells are cancer-fighting T cells modified in the lab to bind and attack cancer cells more effectively. Dr. June has developed new strategies for treating cancer with CAR T therapy and robust culture systems that have enabled CAR T clinical trials. The CAR T cells invented in Dr. June’s lab were awarded “Breakthrough Therapy” status by the Food and Drug Administration for acute leukemia in children and adults in 2014.

“Dr. June’s extraordinary vision and dedication have helped to make the promise of cell-engineering a therapeutic reality while fundamentally changing the way we treat cancer patients,” said Kieren Marr, MD, MBA, Professor of Medicine and Oncology and Director of the Transplant and Oncology Infectious Diseases Program at Johns Hopkins, and 2018-2019 President of the ASCI. “In this exciting and evolving field, built on many brilliant discoveries, his work on immune cell regulation and development of robust T cell culture systems make him an outstanding choice for the Harrington Prize for Innovation in Medicine.”

A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from three countries before selecting the 2019 recipient.

“We are thrilled to join the ASCI in honoring Dr. June and his team’s remarkable achievements, which represent a new paradigm for treating cancer,” said Jonathan Stamler, MD, President of the Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at UH Cleveland Medical Center and Case Western Reserve University School of Medicine. “Dr. June is a true luminary whose work promises enormous impact on human health.”

In addition to receiving a $20,000 honorarium, Dr. June will deliver The Harrington Prize Lecture at the 2019 AAP/ASCI/APSA Joint Meeting on April 5, 2019, publish an essay in the Journal of Clinical Investigation, and speak at the Harrington Scientific Symposium May 23, 2019 in Cleveland.

Dr. June is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston. He did his graduate training in Immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983-86.

The first recipient of The Harrington Prize for Innovation in Medicine, in 2014, was Dr. Harry Dietz (Johns Hopkins University School of Medicine, USA), for his contributions to the understanding of the biology and treatment of Marfan syndrome, a disorder leading to deadly aneurysms in children and adults. The 2015 recipient was Douglas R. Lowy, MD, Chief, Laboratory of Cellular Oncology (The National Cancer Institute, USA), in recognition of his discoveries that led to the development of the Human Papillomavirus vaccine to prevent cervical cancer. The 2016 recipient was Jeffrey M. Friedman, MD, PhD (The Rockefeller University, USA), for his discovery of leptin, which controls feeding behavior and is used to treat related clinical disorders. In 2017, the Prize was awarded jointly to Daniel J. Drucker, MD (Mount Sinai Hospital, Canada), Joel F. Habener, MD (Massachusetts General Hospital, USA) and Jens J. Holst, MD, DMSc (University of Copenhagen, Denmark) for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes. The 2018 recipient was Helen H. Hobbs, MD (UT Southwestern Medical Center, USA) for her discovery of the link between a gene mutation (PCSK9) and lower levels of LDL, which has improved the treatment of high cholesterol.

# # #

Harrington Discovery Institute

The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.

The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines. For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.

University Hospitals

Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 40 outpatient health centers and 200 physician offices in 15 counties throughout northern Ohio. The system’s flagship academic medical center, University Hospitals Cleveland Medical Center, located on a 35-acre campus in Cleveland’s University Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children’s Hospital, ranked among the top children’s hospitals in the nation; University Hospitals MacDonald Women’s Hospital, Ohio’s only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer, pediatrics, women’s health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including “America’s Best Hospitals” from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals – part of The Harrington Project for Discovery & Development. UH is one of the largest employers in Northeast Ohio with 26,000 employees.

UH’s vision is “Advancing the science of health and the art of compassion,” and its mission: “To Heal. To Teach. To Discover.” Follow UH on Facebook @UniversityHospitals and Twitter @UHhospitals. For more information, go to UHhospitals.org.